AU2002218342A1 - Use of a compound antagonist of the esm-1 protein for producing a medicine for treating cancer - Google Patents

Use of a compound antagonist of the esm-1 protein for producing a medicine for treating cancer

Info

Publication number
AU2002218342A1
AU2002218342A1 AU2002218342A AU1834202A AU2002218342A1 AU 2002218342 A1 AU2002218342 A1 AU 2002218342A1 AU 2002218342 A AU2002218342 A AU 2002218342A AU 1834202 A AU1834202 A AU 1834202A AU 2002218342 A1 AU2002218342 A1 AU 2002218342A1
Authority
AU
Australia
Prior art keywords
esm
medicine
protein
producing
treating cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002218342A
Other languages
English (en)
Inventor
David Bechard
Philippe Lassalle
Andre-Bernard Tonnel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut Pasteur de Lille
Institut National de la Sante et de la Recherche Medicale INSERM
Original Assignee
Institut Pasteur de Lille
Institut National de la Sante et de la Recherche Medicale INSERM
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut Pasteur de Lille, Institut National de la Sante et de la Recherche Medicale INSERM filed Critical Institut Pasteur de Lille
Publication of AU2002218342A1 publication Critical patent/AU2002218342A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2002218342A 2000-11-09 2001-11-08 Use of a compound antagonist of the esm-1 protein for producing a medicine for treating cancer Abandoned AU2002218342A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0014422 2000-11-09
FR0014422A FR2816214B1 (fr) 2000-11-09 2000-11-09 Utilisation d'un compose antagoniste de la proteine esm-1 pour la fabrication d'un medicament pour la prevention et/ou le traitement d'un cancer
PCT/FR2001/003475 WO2002038178A1 (fr) 2000-11-09 2001-11-08 Utilisation d'un compose antagoniste de la proteine esm-1 pour la fabrication d'un medicament pour le traitement d'un cancer

Publications (1)

Publication Number Publication Date
AU2002218342A1 true AU2002218342A1 (en) 2002-05-21

Family

ID=8856265

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002218342A Abandoned AU2002218342A1 (en) 2000-11-09 2001-11-08 Use of a compound antagonist of the esm-1 protein for producing a medicine for treating cancer

Country Status (7)

Country Link
US (1) US7306797B2 (ja)
EP (1) EP1335745A1 (ja)
JP (1) JP4121852B2 (ja)
AU (1) AU2002218342A1 (ja)
CA (1) CA2429404A1 (ja)
FR (1) FR2816214B1 (ja)
WO (1) WO2002038178A1 (ja)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040167067A1 (en) * 2002-07-01 2004-08-26 David Griggs ESM-1 gene differentially expressed in angiogenesis, antagonists thereof, and methods of using the same
US20070197452A1 (en) * 2006-02-17 2007-08-23 Mclaurin Joanne Treatment of amyloid-related diseases
EP2200632A2 (en) * 2007-10-24 2010-06-30 Institut Pasteur De Lille The use of a non-glycanated polypeptide for treating a cancer
TWI772927B (zh) * 2015-03-31 2022-08-01 德商英麥提克生物技術股份有限公司 用於腎細胞癌(rcc)免疫治療的新型肽和肽組合物和支架

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10510518A (ja) * 1994-12-09 1998-10-13 ヒューマン ジノーム サイエンシーズ，インコーポレイテッド ヒト血管ｉｂｐ様成長因子
US5747280A (en) * 1995-06-05 1998-05-05 Human Genome Sciences, Inc. Human vascular IBP-like growth factor
US6670328B1 (en) 1997-06-24 2003-12-30 Institut Pasteur De Lille Proteins and peptides derived from protein ESM-1 and their uses in the treatment and diagnosis of diseases linked to leukocyte migration
FR2775691B1 (fr) * 1998-03-05 2000-12-15 Pasteur Institut Anticorps monoclonaux specifiques de la proteine esm-1, et utilisation de ces anticorps pour la detection de la proteine esm-1

Also Published As

Publication number Publication date
WO2002038178A1 (fr) 2002-05-16
FR2816214A1 (fr) 2002-05-10
CA2429404A1 (fr) 2002-05-06
JP4121852B2 (ja) 2008-07-23
JP2004518638A (ja) 2004-06-24
FR2816214B1 (fr) 2005-10-21
EP1335745A1 (fr) 2003-08-20
US7306797B2 (en) 2007-12-11
US20040234526A1 (en) 2004-11-25

Similar Documents

Publication Publication Date Title
AU7031500A (en) Therapeutic quinazoline compounds
AU2002213848A1 (en) Integrated process for the preparation of olefin oxides
HK1080361A1 (en) The use of compound in the preparation of medicaments for treating demyelinating diseases
AU2001284021A1 (en) Quinazoline derivatives, medicaments containing these compounds, their use, and methods for the production thereof
AU2002343739A1 (en) Improved therapy for topical diseases
AU2003224076A1 (en) Antibody combination useful for tumor therapy
AU2002239491A1 (en) Methods for the treatment of cancer and other diseases and methods of developing the same
AU2000258650A1 (en) 2-piperidone compounds for the treatment of cancer
AU2001267831A1 (en) DDS compound and process for the preparation thereof
AU2002217866A1 (en) Geldanamycin derivatives useful for the treatment of cancer
AU2002353366A1 (en) The process of manufacturing a pharmaceutical composition useful for management of cancer
AU2002218342A1 (en) Use of a compound antagonist of the esm-1 protein for producing a medicine for treating cancer
AU2002358469A1 (en) Modified receptors for the discovery of therapeutic ligands
AU2002218750A1 (en) Photoactivated drug therapy
AU2001254712A1 (en) Use of organophosphorous compounds for producing a medicament for treating infections
AU2001287884A1 (en) Halogen compounds for use in medicine
AU2001289127A1 (en) Tumor treatment
AU2002212582A1 (en) Process for preparing (-)- menthol and similar compounds
AU2002348105A1 (en) Oral dosage forms for improving the bioavailability of therapeutic agents
AU2000272704A1 (en) Use of compounds for the treatment of obesity
AU2001271261A1 (en) Therapeutic treatment of cancer with a protein kinase c inhibitor
AU2002232563A1 (en) Compounds for therapy and diagnosis and methods for using same
AU2002339178A1 (en) Quinazoline compounds with therapeutic use
AU2002350513A1 (en) Use of solasonine for the treatment of skin tumors
AU1990195A (en) Use of compounds which inhibit phosphatidic acid formation for the manufacture of a medicament for the treatment of cancer